MAP3K5 and metabolic dysfunction-associated steatohepatitis: ASK1 inhibitor, Selonsertib (GS-444217) ameliorates NASH and improved fibrosis in preclinical studies and in a short-term clinical trial [148] but was not effective in late-phase clinical trials [149].